Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis

Young Eun Chon, Young-Joo Jin, Jihyun An, Hee Yeon Kim, Miyoung Choi, Dae Won Jun, Mi Na Kim, Ji Won Han, Han Ah Lee, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2024;30(suppl):s117-s133. Published online August 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0392

View: 738 Download: 79

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 1995 Download: 140 Web of Science: 4 Crossref: 2

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 2009 Download: 47 Crossref: 1

Snapshot

Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease

Young Chang, Soung Won Jeong, Jae Young Jang

Clin Mol Hepatol. 2024;30(1):129-133. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0356

View: 2834 Download: 156 Crossref: 3

Correspondence

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(1):126-128. Published online November 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0500

View: 1669 Download: 42

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):124-125. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0470

View: 1703 Download: 43 Web of Science: 1 Crossref: 2

Letter to the Editor

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 2207 Download: 53 Web of Science: 2 Crossref: 1

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji

Clin Mol Hepatol. 2024;30(1):113-117. Published online November 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0440

View: 2047 Download: 71 Web of Science: 2 Crossref: 1

Original Article

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review

George Chen, Bubu Banini, Albert Do, Joseph K. Lim

Clin Mol Hepatol. 2023;29(Suppl):S319-S332. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0366

View: 3755 Download: 108 Web of Science: 3 Crossref: 4

Review

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0329

View: 5963 Download: 294 Web of Science: 11 Crossref: 12

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management

Anja Geerts, Sander Lefere

Clin Mol Hepatol. 2023;29(Suppl):S276-S285. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0373

View: 4120 Download: 144 Web of Science: 7 Crossref: 8

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3718 Download: 210 Web of Science: 10 Crossref: 14

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 3669 Download: 123 Web of Science: 6 Crossref: 6

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 4076 Download: 112

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 4004 Download: 137 Web of Science: 5 Crossref: 5

Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease

Karim Seif El Dahan, Darine Daher, Amit G. Singal

Clin Mol Hepatol. 2023;29(Suppl):S207-S219. Published online September 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0247

View: 7993 Download: 185 Web of Science: 9 Crossref: 12

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 6094 Download: 285 Web of Science: 9 Crossref: 10

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 4409 Download: 190 Web of Science: 11 Crossref: 13

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 4302 Download: 231 Web of Science: 9 Crossref: 8

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 4584 Download: 228 Web of Science: 20 Crossref: 19

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 4516 Download: 211 Web of Science: 12 Crossref: 12

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 5793 Download: 219 Web of Science: 10 Crossref: 13

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 5046 Download: 242 Web of Science: 25 Crossref: 26

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 6063 Download: 283 Web of Science: 17 Crossref: 23

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 4684 Download: 179 Web of Science: 30 Crossref: 31

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 12923 Download: 505 Web of Science: 137 Crossref: 155

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 8040 Download: 532 Web of Science: 55 Crossref: 58

Correspondence

Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(4):1050-1051. Published online August 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0310

View: 1917 Download: 39 Crossref: 1

Original Article

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe

Clin Mol Hepatol. 2023;29(4):987-1001. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0035

View: 4624 Download: 295 Web of Science: 13 Crossref: 15

Editorial

Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?

Eugene Han, Yong-ho Lee

Clin Mol Hepatol. 2023;29(4):980-983. Published online August 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0250

View: 2262 Download: 102 Web of Science: 2 Crossref: 2

1 | 2 | 3 | 4 | 5 | 6 | 7 |

Viewed By 5153	MAFLD: How is it different from NAFLD?
Viewed By 4900	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4874	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4581	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4567	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search